Probi and Sinopharm enter strategic partnership in China

Report this content

The Swedish probiotic supplier, Probi® and Sinopharm, one of China’s largest pharmaceutical & healthcare companies enter a partnership to expand the offering of premium probiotic offerings in the Chinese market.

Sinopharm will launch three probiotic supplements within the immune health, bone health and iron absorption areas based on Probi’s scientifically proven probiotic strains.

Zhang Jian Ge, Director Pharmaceutical & Chemical Division of Sinopharm, states: “Sinopharm continues to commit to our strong sense of social responsibility of “caring for life, attending to health”. Guided by our core value “All for health, health for all”, Sinopharm’s recent strategic partnership with Probi, especially its best-in-class R&D capability helps us contribute with positive impact to China’s consumer healthcare industry.”

And she continues: The products have clinically documented positive effects and will be introduced under a new brand to expand Sinopharm’s existing supplement portfolio.”

Probiotics are a high-growth segment in China with a growth rate of 10.3% CAGR in the next 5 years according to Euromonitor.

Veronica Dong, Head of APAC, Probi: “We are excited to partner with Sinopharm, who shares our vision of bringing innovative and scientifically supported products into China and the APAC region. With this partnership Probi has demonstrated its position as a leading probiotic company to capture high growth markets in the region such as China.”

“The partnership between Probi and Sinopharm is an important step in our commercial efforts in offering clinically documented probiotic products to consumers all over the world, and our expansion into China is a good step forward in establishing Probi’s position in the APAC region. In our partnership with Sinopharm we feel commitment and alignment in offering high quality products based upon research, clinical documentation and performance,” says Tom Rönnlund, CEO at Probi.


For further information, please contact:

Tom Rönnlund, CEO, Probi®,
Phone: +46 46 286 89 40, E-mail:

Veronica Dong, Head of APAC, Probi®Phone: +65 6439 2313, E-mail:
Charlotte Beyerholm, Director Marketing & Global Communication, Probi®,
Phone: +46 76 870 94 65, E-mail:



Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical
documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to
more than 40 markets. We hold more than 400 patents globally. Read more at

Probi® is a registered trademark of Probi AB.

ABOUT Sinopharm

China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.
Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.